OnKure Therapeutics, Inc. Class A Common Stock (OKUR)

• Market cap: $61.6M
• 1 day: -3.55%
• 5 days: -12.00%
• 1 month: -17.94%
• 3 months: -53.14%
• 6 months: -75.23%
• Year to date: -45.77%
• 1 year: -75.23%
• 5 years: -75.23%
• 10 years: -75.23%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

93.6% more ownership

Funds ownership: 0% [Q3] → 93.6% (+93.6%) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $30 549% upside
• Avg. target: $31 571% upside
• High target: $32 593% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Oppenheimer Matt Biegler 50% 1-year accuracy 1 / 2 met price target	549% upside $30	Outperform Maintained	11 Mar 2025
Jones Trading Soumit Roy 19% 1-year accuracy 3 / 16 met price target	593% upside $32	Buy Initiated	28 Jan 2025